GS
EW icon

GTS Securities’s Edwards Lifesciences EW Stock Holding History

GTS Securities’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,100
Closed -$4.69M – 2174
2024
Q3 		$4.69M Buy
71,100
+62,000
+681% +$4.5M 0.01% 934
2024
Q2 		$841K Sell
9,100
-18,500
-67% -$1.64M ﹤0.01% 2220
2024
Q1 		$2.64M Sell
27,600
-15,800
-36% -$1.33M ﹤0.01% 1293
2023
Q4 		$3.31M Buy
43,400
+5,500
+15% +$383K 0.01% 1290
2023
Q3 		$2.63M Buy
+37,900
New +$3.05M ﹤0.01% 1314

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

GTS Securities's EW Position: Q2 2026 in Review

GTS Securities sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,847 shares — an estimated $388K sold.

GTS Securities first reported a position in EW in Q3 2023 and held it in 8 quarters. The position peaked at $2.17M in Q4 2023. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • GTS Securities reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 4,847 Edwards Lifesciences shares in Q2 2026, an estimated $388K.
  • GTS Securities first reported a position in Edwards Lifesciences in Q3 2023 and held it in 8 quarters.
  • GTS Securities's Edwards Lifesciences position peaked at $2.17M in Q4 2023.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.